Cocrystal Pharma, Inc.
COCP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | -0.00 | 0.53 |
| FCF Yield | -80.25% | -89.06% | -135.46% | -21.29% |
| EV / EBITDA | -0.72 | 0.41 | 0.55 | -0.13 |
| Quality | ||||
| ROIC | -157.81% | -74.93% | -96.82% | -18.16% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 0.82 | 0.55 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -11.56% | 31.27% | -68.42% | -26.82% |
| Safety | ||||
| Net Debt / EBITDA | 0.46 | 1.26 | 0.96 | 4.22 |
| Interest Coverage | 0.00 | 0.00 | -19,414.50 | -3,555.25 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 3.22 | 0.00 |
| Cash Conversion Cycle | -4,466.90 | -29,404.05 | -814.30 | -880.88 |